Source-grounded facts extracted from Neuphoria Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Neuphoria Therapeutics Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5620(a)).
“ompany was not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s failure to hold a qualified annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June”
Neuphoria Therapeutics Inc. issued common stock.
“the Board declared a dividend of one preferred share purchase right for each outstanding share of the Company’s common stock as of the close of business on October 27, 2025, the record date”
Neuphoria Therapeutics Inc.: Adoption of Certificate of Designations establishing Preferred Shares and their rights (effective 2025-10-27).
“Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. In connection with the adoption of the Rights Agreement referenced in Item 1.01 above, the Board approved the Certificate of Designations establishing the Preferred Shares and the rights, preferences and privileges thereof. The Certificate of Designations was filed with the Secretary of State of the State of Delaware on October 27, 2025.”
Neuphoria Therapeutics Inc. received a nasdaq extension granted notice regarding shareholders (rules 5620(a)).
“September 10, 2025, Nasdaq provided the Company further notice that is has accepted our Plan and granted the Company an extension of 180 calendar days (the “ Compliance Period ”) from the end of the Company’s fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. To this end, the Company intends to file its annual report on Form 10-K on or before September 29, 2025, and thereafter, the Company intends to timely file a proxy statement and notice of shareholder meeting related to the Company’s 2025 annual general shareholder meeting, and further intends to hold such”
Neuphoria Therapeutics Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).
“July 18, 2025, Neuphoria Therapeutics Inc. (the “Company”) received a deficiency notification letter (the “ Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s failure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after”
Neuphoria Therapeutics Inc.: Code of Conduct adopted, applies to all directors, officers and employees.
“Neuphoria has adopted a Code of Conduct (the “Code”), which applies to all directors, officers and employees”
Neuphoria Therapeutics Inc.: Bylaws adopted in connection with redomiciliation.
“rights of our shareholders are no longer governed by Bionomics’ organizational documents and instead are now governed by Neuphoria’s Amended and Restated Certificate of Incorporation and its bylaws”
Neuphoria Therapeutics Inc.: Amended and Restated Certificate of Incorporation adopted in connection with redomiciliation.
“rights of our shareholders are no longer governed by Bionomics’ organizational documents and instead are now governed by Neuphoria’s Amended and Restated Certificate of Incorporation”
Neuphoria Therapeutics Inc. underwent a change of control involving Neuphoria Therapeutics Inc. (closed 2024-12-23).
“On December 23, 2024 US time (“Effective Date”), the redomiciliation (“Redomiciliation”) of Bionomics Limited, an Australian corporation (“Bionomics”), was implemented under Australian law in accordance with a Scheme Implementation Agreement (as amended) between Bionomics and Neuphoria Therapeutics Inc., a Delaware corporation (“Neuphoria”).”
Aaron Weaver resigned as Director at Neuphoria Therapeutics Inc..
“On October 9, 2024, Mr. Aaron Weaver, a member of the Board of Directors of Bionomics Limited (the “Company”), provided the Company’s board with notice that he was resigning from the Board of Directors, effective October 9, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.